Since inception, CommBio Therapeutics has received funding from a number of leading healthcare investors (financial and strategic) in China.

We at CommBio welcome opportunities to collaborate with research institutions, hospitals, pharmaceuticals, biotechs and organizations globally to further advance the development of engineered bacterial drug candidates, as well as the research in the field of intestinal biology, so we can bring cure to patients all over the world.

If you are interested in discussing potential partnership with CommBio, please contact us, we look forward to hearing from you.